Skip to main content

Advertisement

SpringerLink
Log in

Bladder Outlet Obstruction and BPH

  • Geriatric Bladder Dysfunction (G Ghoniem, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

It is well known that age is the major risk factor for benign prostatic hyperplasia (BPH). A histologic diagnosis of BPH will develop in approximately half of men over 40. Of these men, approximately 50 % will develop notable lower urinary tract symptoms (LUTS), which increase in prevalence between age 40 and 80 [1]. The degree of prostatic enlargement, which impacts the severity of symptoms experienced, is highly variable. The presence of lower urinary tract symptoms is often indicative of bladder outlet obstruction (BOO) secondary to BPH, especially in the elderly. The treatment of BPH, which includes medical, minimally invasive, and surgical therapies, aims to improve subjective symptoms and quality of life. This review focuses on novel therapies for BOO secondary to BPH in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5):112.

    Google Scholar 

  2. Abrams P. New words for old: lower urinary tract symptoms for “prostatism”. BMJ. 1994;308(6934):929–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Silverman WM. “Alphabet soup” and the prostate: LUTS, BPH, BPE, and BOO. J Am Osteopath Assoc. 2004;104(2 Suppl 2):S1–4.

    PubMed  Google Scholar 

  4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.

    CAS  PubMed  Google Scholar 

  5. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980;14(1):29–35.

    Article  CAS  PubMed  Google Scholar 

  6. Franks LM. Benign nodular hyperplasia of the prostate; a review. Ann R Coll Surg Engl. 1953;14(2):92–106.

    CAS  PubMed  Google Scholar 

  7. Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health. 2013;31(2):103–25. doi:10.5534/wjmh.2013.31.2.103.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014. doi:10.1007/s40618-014-0051-3.

    PubMed  Google Scholar 

  9. Lim CS, Abrams P. The Abrams-Griffiths nomogram. World J Urol. 1995;13(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  10. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84(1):14–5.

    Article  CAS  PubMed  Google Scholar 

  11. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn. 1997;16(1):1–18.

    Article  CAS  PubMed  Google Scholar 

  12. Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International SC. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181(4):1779–87. doi:10.1016/j.juro.2008.11.127.

    Article  CAS  PubMed  Google Scholar 

  13. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. 2014. doi:10.1111/bju.12745.

    PubMed  Google Scholar 

  14. Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing. 1994;23(5):360–4.

    Article  CAS  PubMed  Google Scholar 

  15. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65(2):389–98. doi:10.1016/j.eururo.2013.10.015.

    Article  PubMed  Google Scholar 

  16. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

    Article  PubMed  Google Scholar 

  17. Kalisch Ellett LM, Pratt NL, Barratt JD, Rowett D, Roughead EE. Risk of medication-associated initiation of oxybutynin in elderly men and women. J Am Geriatr Soc. 2014;62(4):690–5. This is important specifically for the elderly because it highlights the potential for commonly used medications to contribute to urinary incontinence, as well as the need for additional research and better treatment options.

    Article  PubMed  Google Scholar 

  18. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101 Suppl 3:17–21. doi:10.1111/j.1464-410X.2008.07497.x.

    Article  PubMed  Google Scholar 

  19. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-–40. doi:10.1016/j.eurouro.2013.03.004. Presents the most up-to-date guidelines on the treatment of male LUTS.

    Article  PubMed  Google Scholar 

  20. Maserejian NN, Chen S, Chiu GR, Araujo AB, Kupelian V, Hall SA, et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J Urol. 2014;191(1):107–13. doi:10.1016/j.juro.2013.07.005.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Chen Y, Zhang X, Hu X, Deng Y, Chen J, Li S, et al. The potential role of a self-management intervention for benign prostate hyperplasia. Urology. 2012;79(6):1385–8. doi:10.1016/j.urology.2011.11.091.

    Article  PubMed  Google Scholar 

  22. Yap TL, Brown C, Cromwell DA, van der Meulen J, Emberton M. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int. 2009;104(8):1104–8. doi:10.1111/j.1464-410X.2009.08497.x.

    Article  PubMed  Google Scholar 

  23. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–53.

    Article  CAS  PubMed  Google Scholar 

  24. Kashyap M, Tu LM, Tannenbaum C. Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr. 2013;13(1):57. doi:10.1186/1471-2318-13-57.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int. 2005;95 Suppl 4:19–28. doi:10.1111/j.1464-410X.2005.05487.x.

    Article  CAS  PubMed  Google Scholar 

  26. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013;347:f6320. doi:10.1136/bmj.f6320.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology. 2011;118(4):730–5. doi:10.1016/j.ophtha.2010.08.039. Focuses on a potential side effect of alpha-blockers that patients should be aware of.

    Article  PubMed  Google Scholar 

  28. Hargitai J, Vezendi L, Vigstrup J, Eisgart F, Lundbye-Christensen S, Hargitai B, et al. Comparing the efficacy of mydriatic cocktail-soaked sponge and conventional pupil dilation in patients using tamsulosin—a randomized controlled trial. BMC Ophthalmol. 2013;13:83. doi:10.1186/1471-2415-13-83.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Lorente R, de Rojas V, Vazquez de Parga PV, Moreno C, Varela J, Landaluce ML, et al. Intracameral phenylephrine 1.5 % for prophylaxis against intraoperative floppy iris syndrome: prospective, randomized fellow eye study. Ophthalmology. 2012;119(10):2053–8.

  30. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63. doi:10.1056/NEJM199802263380901.

    Article  CAS  PubMed  Google Scholar 

  31. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. doi:10.1056/NEJMoa030656.

    Article  CAS  PubMed  Google Scholar 

  32. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17–25. doi:10.1016/j.clinthera.2007.01.018.

    Article  CAS  PubMed  Google Scholar 

  33. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24. doi:10.1056/NEJMoa030660.

    Article  CAS  PubMed  Google Scholar 

  34. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202. doi:10.1056/NEJMoa0908127.

    Article  CAS  PubMed  Google Scholar 

  35. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66. doi:10.1111/jsm.12525.

    Article  CAS  PubMed  Google Scholar 

  36. Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81–90. doi:10.1517/14740338.2013.742885.

    Article  CAS  PubMed  Google Scholar 

  37. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. doi:10.1016/j.eururo.2009.09.035.

    Article  PubMed  Google Scholar 

  38. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461–6.

    Article  CAS  PubMed  Google Scholar 

  39. Nickel JC, Barkin J, Koch C, Dupont C, Elhilali M. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J. 2008;2(1):16–21.

    PubMed Central  PubMed  Google Scholar 

  40. Yassin DJ, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, Hammerer PG. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. 2013. doi:10.1007/s00345-013-1187-z.

    PubMed  Google Scholar 

  41. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28. doi:10.1001/jama.296.19.2319.

    Article  CAS  PubMed  Google Scholar 

  42. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182(6):2825–30. doi:10.1016/j.juro.2009.08.023.

    Article  PubMed  Google Scholar 

  43. Abrams P, Kaplan S, De Koning GH, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004.

    Article  CAS  PubMed  Google Scholar 

  44. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253–6.

    Article  CAS  PubMed  Google Scholar 

  45. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update Arch Intern Med. 1997;157(14):1531–6.

    Article  CAS  Google Scholar 

  46. Kraus SR, Bavendam T, Brake T, Griebling TL. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging. 2010;27(9):697–713. doi:10.2165/11539020-000000000-00000.

    Article  PubMed  Google Scholar 

  47. Otsuki H, Kosaka T, Nakamura K, Mishima J, Kuwahara Y, Tsukamoto T. Beta 3 adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53–60.

    Article  CAS  PubMed  Google Scholar 

  48. Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;9:CD004135. doi:10.1002/14651858.CD004135.pub3.

    PubMed  Google Scholar 

  49. Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014;113(4):615–22. doi:10.1111/bju.12540.

    Article  PubMed  Google Scholar 

  50. Somani BK, Hacking N, Bryant T, Coyne J, Flowers D, Harris M, et al. Prostate artery embolization (PAE) for benign prostatic enlargement (BPE). BJU Int. 2014. doi:10.1111/bju.12672.

    Google Scholar 

  51. Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm: results from a single-center prospective study. Urology. 2014. doi:10.1016/j.urology.2014.04.028.

    PubMed  Google Scholar 

  52. Moreira AM, Marques CF, Antunes AA, Nahas CS, Nahas SC, de Gregorio Ariza MA, et al. Transient ischemic rectitis as a potential complication after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol. 2013;36(6):1690–4. doi:10.1007/s00270-013-0739-3.

    Article  PubMed  Google Scholar 

  53. Bozkurt IH, Yalcinkaya F, Sertcelik MN, Zengin K, Ekici M, Yigitbasi O. A good alternative to indwelling catheter owing to benign prostate hyperplasia in elderly: Memotherm prostatic stent. Urology. 2013;82(5):1004–7. doi:10.1016/j.urology.2013.07.004.

    Article  PubMed  Google Scholar 

  54. Ogiste JS, Cooper K, Kaplan SA. Are stents still a useful therapy for benign prostatic hyperplasia? Curr Opin Urol. 2003;13(1):51–7. doi:10.1097/01.mou.0000049385.71470.43.

    Article  PubMed  Google Scholar 

  55. Barber NJ, Roodhouse AJ, Rathenborg P, Nordling J, Ellis BW. Ease of removal of thermo-expandable prostate stents. BJU Int. 2005;96(4):578–80. doi:10.1111/j.1464-410X.2005.05687.x.

    Article  PubMed  Google Scholar 

  56. Armitage JN, Rashidian A, Cathcart PJ, Emberton M, van der Meulen JH. The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int. 2006;98(4):806–10. doi:10.1111/j.1464-410X.2006.06399.x.

    Article  CAS  PubMed  Google Scholar 

  57. Kimata R, Nemoto K, Tomita Y, Takahashi R, Hamasaki T, Kondo Y. Efficacy of a thermoexpandable metallic prostate stent (Memokath) in elderly patients with urethral obstruction requiring long-term management with urethral Foley catheters. Geriatr Gerontol Int. 2014. doi:10.1111/ggi.12309.

    PubMed  Google Scholar 

  58. Devonec M, Dahlstrand C. Temporary urethral stenting after high-energy transurethral microwave thermotherapy of the prostate. World J Urol. 1998;16(2):120–3.

    Article  CAS  PubMed  Google Scholar 

  59. Brierly RD, Mostafid AH, Kontothanassis D, Thomas PJ, Fletcher MS, Harrison NW. Is transurethral resection of the prostate safe and effective in the over 80-year-old? Ann R Coll Surg Engl. 2001;83(1):50–3.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Thomas R. Jarvis, Bilal Chughtai, and Steven A. Kaplan declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, Weill Cornell Medical College, 425 E 61st street, 12th FL, New York, NY, 10065, USA

    Thomas R. Jarvis, Bilal Chughtai & Steven A. Kaplan

  2. Iris Cantor Men’s Health Center, Weill Cornell Medical College, 425 E61st Street, 12th Floor, New York, NY, 10065, USA

    Thomas R. Jarvis, Bilal Chughtai & Steven A. Kaplan

Authors
  1. Thomas R. Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bilal Chughtai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven A. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bilal Chughtai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jarvis, T.R., Chughtai, B. & Kaplan, S.A. Bladder Outlet Obstruction and BPH. Curr Bladder Dysfunct Rep 9, 372–378 (2014). https://doi.org/10.1007/s11884-014-0263-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-014-0263-6

Keywords

Search

Navigation